Abstract:Background In Parkinson's disease (PD) and Parkinson plus syndrome (PPS), inflammation is recognized as a relevant or contributing factor in the advancement of the diseases. For this reason, numerous biomarkers signaling immune alteration in both the central and peripheral nervous systems have been evaluated in PD and PPS. Nonetheless, the comprehensive inflammatory indices derived from readily available standard blood tests in PD, PPS, and healthy controls (HC) were rarely evaluated especially in the early stage of the diseases. Objective The aim of this study is to explore the serum level of peripheral inflammatory markers among the patients and investigate whether these markers contribute to symptoms. Method Clinical data and blood test results from drug naïve, early-stage 139 PD and 87 PPS patients, along with 139 age- and sex-matched healthy controls (HC) to PD were enrolled, with exclusion criteria applied to conditions potentially affecting inflammation. The study examined the disparities in peripheral inflammation among the groups, using total and subpopulation of white blood cells (WBCs), platelet count, red cell distribution width (RDW), high-density lipoprotein cholesterol (HDL-C), and other composite values reflecting inflammation including RDW to platelet ratio (RPR), neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), neutrophil to HDL-C ratio (NHR), monocyte to HDL-C ratio (MHR), lymphocyte to HDL-C ratio (LHR), platelet to HDL-C ratio (PHR), systemic inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI). Result The MHR values were significantly higher in both PD and PPS groups compared to HC ( p < 0.001 ), and NHR was significantly higher in the PPS group only compared to the HC group ( p < 0.001 ). However, no significant differences in all the inflammatory markers were observed between PPS and PD ( p > 0.05 ). Subgroup analysis of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) patients revealed significantly higher NHR and MHR levels compared to the HC group ( p = 0.025, p = 0.050, respectively ), with no significant difference among PSP, MSA, and PD groups. After adjustment for age, sex, and disease duration, MHR was positively associated with H&Y in the total population (β = 0.288, p < 0.001), negatively associated with MMSE in the PD group (β = -0.245, p = 0.017), and positively associated with both H&Y (β = 0.432, p < 0.001 ) and UPDRS part II (β = 0.295, p = 0.018 ) in PPS group. Conclusion NHR and MHR values are not effective as reliable diagnostic markers due to overlap among groups and their limited discriminative capacity in ROC analyses. However, MHR may potentially serve as an indicator reflecting peripheral inflammation in the early stage of PD and PPS compared to HC.

Maxillary Midline Diastema: A Case Report Involving a Combined Orthodontic/Maxillofacial Approach

Effects of Cerebral Blood Flow and White Matter Integrity on Cognition in CADASIL Patients

The associations between common neuroimaging parameters of Progressive Supranuclear Palsy in magnetic resonance imaging and non-specific inflammatory factors - pilot study

Platelet-to-lymphocyte ratio and neutrophil-tolymphocyte ratio may reflect differences in PD and MSA-P neuroinflammation patterns.

Doping of single polymeric nanoparticles.

Relationships between PET and blood plasma biomarkers in corticobasal syndrome

Peripheral immune profile and neutrophil‐to‐lymphocyte ratio in progressive supranuclear palsy: Case–control study and meta‐analysis

Progressive Supranuclear Palsy: Subcortical Tau Depositions Are Associated with Cortical Perfusion in Frontal and Limbic Regions

Discriminative pattern of reduced cerebral blood flow in Parkinson’s disease and Parkinsonism-Plus syndrome: an ASL-MRI study

Combination of blood flow asymmetry in the cerebral and cerebellar hemispheres on brain perfusion SPECT predicts 5-year outcome in patients with symptomatic unilateral major cerebral artery occlusion

Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Detection of misery perfusion in the cerebral hemisphere with chronic unilateral major cerebral artery steno-occlusive disease using crossed cerebellar hypoperfusion: comparison of brain SPECT and PET imaging

Clinical application of brain perfusion SPECT/CT imaging with NeuroGamTM software in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease

Quantitative brain stem assessment in discriminating neurodegenerative disorders from normal pressure hydrocephalus

Accumulation of Tau Protein, Metabolism and Perfusion—Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)

Monocyte to High-density Lipoprotein Cholesterol Ratio Reflects the Peripheral Inflammatory State in Parkinsonian Disorders

Treating hypertension with guidelines in general practice

Reaction Mechanisms of C 2 Cl 3 + NO 2 via Nitro and Nitrite Adducts

Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson Disease patients

The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-high-density-lipoprotein ratio are correlated with the severity of Parkinson's disease